CORDIS
EU research results

CORDIS

English EN
Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) duringEbola virus infection in non-human primates  humans

Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) duringEbola virus infection in non-human primates humans

Objective

The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health crisis shifted into a complex emergency, with significant, social, economic, humanitarian, political and security dimensions. Till date, no effective medicine has been proven to be effective against EBOV. As a result, it is immensely difficult to mitigate the current outbreak as well as prevent further outbreaks in this region. On Sept 4-5 2014, the WHO gathered expertise on experimental therapies and vaccines and their role in containing the Ebola outbreak in West Africa. During this consultation, experts identified several therapeutic and vaccine interventions that should be the focus of priority evaluation. Among these candidates is the existing antiviral drug Favipiravir, that has proven activity against many RNA viruses in vivo and in vitro including Ebola. Favipiravir is known to inhibit viral gene replication within infected cells to prevent propagation among which it inhibits viral gene replication within infected cells to prevent propagation. Hence, Favipiravir is currently aimed as a curative option in severe pandemic flue. Furthermore, there is currently enough stock of Favipiravir to even treat more than 20.000 patients, and the producer of Favipiravir, Toyoma Chemical/Fujifilm in Japan is willing to rapidly upscale the production of this drug. This drug has been extensively tested in humans and approved in Japan for treatment and prevention of influenza. The drug has shown an excellent safety profile in more than 2000 patients tested and no major adverse effect were reported. The current crisis requires both an immediate response to treat patients and prevent the further spread of the epidemic, as well as long term commitment in the complex sociocultural context. REACTION! will address both needs.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 240 726

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

ASSOCIATION POUR LE DEVELOPPEMENT DE L'ENSEIGNEMENT ET DES RECHERCHES AUPRES DES UNIVERSITES, DES CENTRES DE RECHERCHE ET DES ENTREPRISES D'AQUITAINE

France

EU Contribution

€ 477 262

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN

Germany

EU Contribution

€ 64 250

INSTITUT PASTEUR

France

EU Contribution

€ 74 025

ECOLE NORMALE SUPERIEURE DE LYON

France

EU Contribution

€ 142 500

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 88 500

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 86 250

DRUG DISCOVERY FACTORY BV

Netherlands

EU Contribution

€ 127 062,50

UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 72 359

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 4 250

UNIVERSITE CHEIKH ANTA DIOP DE DAKAR

Senegal

EU Contribution

€ 134 375

Department of Health

United Kingdom

EU Contribution

€ 64 250

FONDATION POUR L INSTITUT DE HAUTES ETUDES INTERNATIONALES ET DU DEVELOPPEMENT

Switzerland

Project information

Grant agreement ID: 666092

  • Start date

    1 November 2014

  • End date

    31 October 2017

Funded under:

H2020-EU.3.1.

  • Overall budget:

    € 2 755 719,89

  • EU contribution

    € 2 575 809,50

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France